Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Cosmo Pharmaceuticals NV : annual earnings release

share with twitter share with LinkedIn share with facebook
03/26/2019 | 09:15am EDT

The company will report its earnings for FY 2018 on 03/29/2019. Generally, the company reports earnings better than estimates. In recent months, the 2 analysts from Thomson Reuters consensus have revised their EPS estimates downward.

Annual earnings per share is expected at -1.41 EUR for 2018 (- 35.8% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million €
Released
Forecast
Spread
60,6
60,3
0,56%
67,7
64,7
4,6%
67,2
62,9
6,9%

69,3

79,5
Operating income (EBITDA)
Million €
Released
Forecast
Spread
0,97
-4,12
124%
24,0
18,3
32%



-15,3

-22,7
Operating profit (EBIT)
Million €
Released
Forecast
Spread
-7,53
-15,5
51%
21,0
14,1
49%
-15,5
-13,4
-16%

-18,5

-33,0
Pre-Tax Profit (EBT)
Million €
Released
Forecast
Spread


27,5
10,7
157%
-32,4
-36,1
10%

-17,6

-32,6
Net income
Million €
Released
Forecast
Spread
248
248
0,08%
19,3
6,62
192%
-32,4
-32,1
-1,2%




EPS
 €
Released
Forecast
Spread
17,2
17,6
-2,0%
1,37
0,47
194%
-2,19
-2,00
-9,3%

-1,41

-2,70
Announcement Date03/23/201603/24/201703/26/2018

© MarketScreener.com 2019

share with twitter share with LinkedIn share with facebook
All news about COSMO PHARMACEUTICALS N.V.
10/12COSMO PHARMACEUTICALS N : Acacia Pharma completes drawdown from EUR25 million lo..
AQ
08/28COSMO PHARMACEUTICALS N : announces FDA Approval for Cassiopea's Winlevi, First-..
AQ
08/27Cassiopea gets U.S. FDA approval for acne treatment Winlevi
RE
08/27COSMO PHARMACEUTICALS N : announces FDA Approval for Cassiopea's Winlevi ® (clas..
PU
08/27Cosmo Pharmaceuticals announces FDA Approval for Cassiopea's Winlevi® (clasco..
TE
08/24COSMO PHARMACEUTICALS N : NV - Methylene Blue MMX approved in Europe for the vis..
AQ
08/21Methylene Blue MMX approved in Europe for the visualization of colorectal les..
TE
08/13REDHILL BIOPHARMA : and Cosmo Pharmaceuticals to Expand Strategic Partnership wi..
AQ
08/13Cosmo and RedHill Biopharma to Expand Strategic Partnership with Exclusive Li..
TE
07/30Cosmo Half-Year Report 2020
TE
More news
Financials
Sales 2020 52,6 M 62,4 M 62,4 M
Net income 2020 -8,55 M -10,1 M -10,1 M
Net cash 2020 37,3 M 44,2 M 44,2 M
P/E ratio 2020 -113x
Yield 2020 -
Capitalization 1 086 M 1 287 M 1 288 M
EV / Sales 2020 19,9x
EV / Sales 2021 16,8x
Nbr of Employees 261
Free-Float 45,8%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 93,85 €
Last Close Price 75,10 €
Spread / Highest target 48,2%
Spread / Average Target 25,0%
Spread / Lowest Target -10,3%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chŕ Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.5.08%1 287
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999